Abstract
The goal of this research was to investigate whether the suppression of hsCRP level increase is related to high-dose simvastatin pre-treatment in patients undergoing primary percutaneus coronary intervention. Previous randomized trials have demonstrated that high-dose statin pre-treatment reduced the inflammation response after coronary intervention in patients with stable angina pectoris and acute coronary syndrome. However, there was only few of studies that investigate the benefit of high-dose statin pre-treatment in acute STEMI patients undergoing primary PCI. Simvastatin is commonly prescribed for Indonesian patients and generally covered by national health insurance.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
